The collaboration brings together Tetra Pharm Technologies'
expertise in enabling technology with Glysious' proprietary
transdermal drug delivery system, renowned for its effectiveness,
comfort, and convenience.
COPENHAGEN, Denmark,
April 24, 2024 /PRNewswire/ --
Tetra Pharm Technologies and Glysious are pleased to announce
a strategic collaboration aimed at developing a ground-breaking
transdermal drug delivery system complementing several of Tetra
Pharm Technologies' pipeline candidates. The joint invention aims
to revolutionize transdermal release of "difficult-to-formulate"
compounds targeting the endocannabinoid system.
Tetra Pharm Technologies has focused intensively on formulation
expertise, that is, how the molecules are effectively integrated
with a drug delivery system to reach their desired targets.
Glysious has worked rigorously on the development of an adhesive
patch for transdermal drug delivery since the company's
incorporation in 2020.
"The Glysious technology enables precision, sustained dosing,
and allows for a high drug load and effective emptying of patches.
The transdermal patches remain in place and are very comfortable
and convenient to use, resulting in improved patient compliance.
However, we have identified challenges with standard formulation
strategies, not providing acceptable drug release due to
shortcomings of the formulation matrix", says Professor,
Dr.Techn. Anne Ladegaard Skov, Chief
Scientific Officer, Glysious.
Back in 2023 Glysious and Tetra Pharm Technologies performed
early in-vitro feasibility tests, integrating Tetra Pharma
Technologies' proprietary enabling technology for delivery of
poorly soluble compounds with Glysious' patch.
Dr. Morten Allesø, Chief Scientific Officer, Tetra Pharm
Technologies, adds: "Although both parties were aware of the
uniqueness of our respective technologies, we were positively
surprised to find a five-fold increase in performance of our
combination product compared to conventional formulation
technologies. This is truly remarkable, and we consider it our
shared obligation to further advance this technology to the benefit
of the patients."
The objectives of the collaboration include conducting
comprehensive in-vitro and in-vivo studies to evaluate the
performance and efficacy of the combined drug delivery system.
Additionally, Tetra Pharm Technologies and Glysious plan to pursue
a common patent for the joint invention, ensuring that their
innovative technology remains protected and exclusive.
"We are excited to collaborate with the innovative team in
Tetra Pharm Technologies on this transdermal drug delivery system
paving the way for commercialization and scaling of the Glysious
technology within the pharma segment", says Stina Bjerg Nielsen, Chief Executive Officer,
Glysious.
Martin Rose, Chief Executive
Officer, Tetra Pharm Technologies, concludes: "The collaboration
represents a unique opportunity to harness the synergies between
our respective technologies. By combining our expertise, we aim to
develop a transdermal drug delivery system that offers superior
efficacy, convenience, and patient compliance, supporting several
of our pipeline programs".
As part of the collaboration, the partners will exchange
expertise, knowledge, and resources. In addition, Tetra Pharm
Technologies and Glysious will conduct joint research, experiments,
and tests as required for the development of a joint patent. The
scope of the collaboration is focused on disease indications such
as pain, sleep disorders, and appetite regulation.
About Tetra Pharm Technologies
Tetra Pharm Technologies is a
Danish biopharmaceutical company established in 2018 with
a vision to be a leader in research and development of
pharmaceutical drugs for the treatment of diseases related to the
endocannabinoid system. For more information, please visit
www.tetrapharm.eu
About Glysious
Glysious is a Danish medtech company, incorporated in 2020, that
develops patches, creams, spray, and foams with controlled release
of active ingredients for cosmetics and life science
applications. For more information, please visit
www.glysious.com
For further information
Jacob Schlundt
Chief Marketing Officer
Tetra Pharm Technologies
schlundt@tetrapharm.eu
+45 51976225
Stina Bjerg Nielsen
Chief Executive Officer
Glysious
sbn@glysious.com
+45 3053 5393
Photo -
https://mma.prnewswire.com/media/2393210/Tetra_Pharm_Technologies_Deal.jpg
Logo -
https://mma.prnewswire.com/media/1988863/Tetra_Pharm_Technologies_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/tetra-pharm-technologies-and-glysious-announce-collaboration-to-develop-transdermal-combination-drugs-targeting-the-endocannabinoid-system-302123136.html